Breaking News, Collaborations & Alliances

Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza

Aims to enable the potential future commercial launch of sabirnetug (ACU193).

Author Image

By: Charlie Sternberg

Associate Editor

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta (Aβ) oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), has extended its collaboration with Lonza to enable the potential future commercial launch of sabirnetug (ACU193).   Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in patients with Alzheimer’s disease (AD). Soluble A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters